Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement

Abstract

Objectives To determine the effectiveness of golimumab (GLM) in improving joint, periarticular structures and cutaneous manifestations in patients with moderate to severe psoriatic arthritis (PsA) with cutaneous psoriasis in different real-life clinical settings and 48-month drug survival. Methods Clinical and laboratory records were collected from PsA patients treated with GLM at baseline (T0) and after 6, 12, 24, 36, and 48 months of treatment. Comparisons were performed using a paired t-test or Wilcoxon test. Drug survival rates were analyzed using Kaplan–Meier estimates. p value < 0.05 was considered statistically significant. Results Data from 105 patients were collected. PsO occurred in 80% of patients and enthesitis in 78%, peripheral and axial arthritis in 63.8% and 35.3%, respectively, while erosions in 36.2%. The main comorbidities were cardiovascular diseases (31.4%) and metabolic syndrome (MetS) (19%). A statistically significant improvement in articular and cutaneous psoriasis was registered at T48 of GLM-therapy in clinical (DAPSA p < 0.0001; PASI p < 0.01; BASDAI p < 0.0001) and laboratory (CRP < 0.05) indexes. Gender (p = 0.652), BMI (p = 0.655), smoking habit (p = 0.466), and line of treatment (p = 0.208) did not affect treatment efficacy nor persistence. At T48, 42% of patients discontinued GLM: the most frequent reason was an insufficient response or loss of efficacy (28.6%). Conclusion A 48-month GLM high drug persistence of PsA patients was observed in real-life, in patients presenting high disease activity, elevated prevalence of comorbidities, and more than one line of treatment at baseline. Patients’ characteristics as gender, smoke, BMI, different lines of treatment, and concomitant methotrexate treatment affected treatment persistence, making GLM effective and safe in moderate-severe PsA in a long-term real-life setting. Key Points• Golimumab was effective in psoriatic arthritis, including both musculoskeletal and cutaneous manifestations. • Golimumab effectiveness and drug survival were not affected by comorbidities and patient-related characteristics. • The 4-year drug survival curves confirm the efficacy and safety of golimumab in psoriatic arthritis patients in a real-life setting.

Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

“…A Spanish study demonstrated comorbidities increase drug discontinuation in PsA and other SpA (32). Another study revealed a significant association between first bDMARD discontinuation and any metabolic comorbidity (46); contrasting results have been reported (47,48). Notably, a higher Charlson comorbidity index (CCI) appeared to be associated with poorer bDMARD adherence, as reported elsewhere (32,40).…”

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

“…The 7‐year retention rate was 39.5% in a previous analysis of the registry (Pombo‐Suarez et al., 2021); 14 the rate in the current analysis was similar, at 37.7%, and remained the same at year 8. Different studies have reported 3‐, 4‐, or 5‐year retention rates for golimumab ranging from 35% to 65% (Aaltonen et al., 2017; Alegre‐Sancho et al., 2021; Chimenti et al., 2022; Michelsen et al., 2020; Serrano_Benavente et al., 2022; Thomas et al., 2018), and a systematic review reported 3‐year golimumab retention rates of 32%–67% (Svedbom, Storck et al., 2017). To the best of our knowledge, the current analysis is the first to report on the golimumab retention rate during 8 years of follow‐up in routine clinical practice in Spain.…”